CONFERENCE DIRECTORS

Helen K. Chew, M.D.
Professor of Medicine
Division of Hematology and Oncology
Department of Internal Medicine
UC Davis School of Medicine

Primo Lara, Jr., M.D.
Professor of Medicine
Division of Hematology and Oncology
Department of Internal Medicine
UC Davis School of Medicine

PRESENTED BY

UC DAVIS
COMPREHENSIVE CANCER CENTER

SPONSORED BY:
THE MEDICAL EDUCATOR CONSORTIUM

16th Annual Advances in Oncology 2015

September 25–26, 2015

Hyatt Regency | Sacramento, CA

(The September 25th conference is held at UC Davis Medical Education Building)
The 16th Annual Advances in Oncology program will bring together academic and community oncologists for the purpose of educating participants on the state-of-the-art clinical management of a wide variety of solid and hematologic malignancies. The program is designed to update physicians and other cancer healthcare providers on recent advances and new diagnostic and treatment modalities in hematologic, breast, lung, gastrointestinal, and genitourinary cancers. This course is intended for physicians and cancer health care providers, including medical, surgical and radiation oncologists, nurses, physician assistants, pharmacists and other interested health care professionals. The conference includes didactic sessions from national oncology leaders and case-based panel discussions involving academic and community oncologists.

EDUCATIONAL OBJECTIVES

At the conclusion of this symposium, you should be able to:

1. Discuss advances in prognostic and predictive biomarkers and potential applications in therapeutic decision making.
2. Integrate targeted and traditional therapeutic modalities in the treatment of cancer.
3. Assess newly validated treatment options for patients with solid tumors or hematologic malignancies.
4. Apply data from recent clinical trials to determine the optimal course of therapy in defined patient populations, with emphasis on novel agents including mTOR inhibitors, ALK inhibitors, monoclonal antibodies, multi-targeted tyrosine kinase inhibitors, and inhibitors of cyclin kinase 4 and 6, among others.

NEEDS ASSESSMENT

The diagnosis, risk stratification, and multi-modality state-of-the-art treatment of hematologic and solid malignancies are rapidly evolving. The development of molecular prognostic assays and novel targeted therapies provides promising tools for personalized medicine.

As a result of prior course participant evaluations and needs assessment surveys, the need for cutting edge information on prognostic markers and appropriate application of novel therapies has been identified. This year's conference will specifically address these needs in the common malignancies identified by past participants as essential to their practice, including solid and hematologic cancers. The timing of this meeting in the fall allows for the latest findings in clinical cancer research from major hematology and oncology conferences to be presented and discussed. This educational activity also meets a unique need for the Northern California Sacramento Valley to provide a group of networked and collaborating oncologists a forum to discuss the most recent developments in oncology care in the context of local treatment approaches, patient populations, and open clinical trials.

The course is designed to change physician competence in oncology care. State of the art lectures and panel discussions from local and national oncologists will provide ample discussions on the applications and challenges of new prognostic tools and targeted and cytotoxic therapies. Pre-lecture and post-lecture audience response systems (evaluations) will be used in outcome measures.

ACCREDITATION

The Medical Educator Consortium is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT HOURS

The Medical Educator Consortium designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

DISCLOSURE

The Medical Educator Consortium (MEC) adheres to the ACCME Standards for Commercial Support. All persons that will be in a position to control the content of the CME Activity are required to disclose all relevant financial relationships. Faculty disclosure forms outlining this information will be made available to all participants prior to educational activity. MEC has also implemented a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.

NURSING CONTINUING MEDICAL EDUCATION

Continuing Medical Education is acceptable for meeting RN continuing education requirements, as long as the course is AMA PRA Category 1 Credits™, and has been taken within the appropriate time frames.
The conference includes didactic sessions from national oncology leaders and case-based panel discussions involving academic and community care professionals. The conference aims to educate physicians and other cancer healthcare providers on the state-of-the-art developments in oncology care in the context of local treatment approaches, patient group of networked and collaborating oncologists a forum to discuss the most recent developments in oncology care in the context of local treatment approaches, patient management and medicine.

At the conclusion of this symposium, you should be able to:

1. Integrate targeted and traditional therapeutic modalities in the treatment of cancer.
2. Assess newly validated treatment options for patients with solid tumors or hematologic malignancies.
3. Evaluate and integrate new diagnostic and predictive biomarkers and potential developments in oncology care.

The program is designed to update physicians and other cancer healthcare providers and community oncologists for the purpose of educating participants on the state-of-the-art developments in oncology care in the context of local treatment approaches, patient management and medicine.

The Medical Educator Consortium designates this live activity for a maximum of 7.0 CREDIT HOURS in the field of Medicine to provide continuing medical education for physicians.

DISCLOSURE

PRA Category 1 Credit(s)™

The content of this program is supported by educational grants from Amgen and Genentech.

AGENDA

SATURDAY, SEPTEMBER 26TH

8:00 am Breakfast Symposia (non CME)

8:45 am Adjourn for the day

FRIDAY, SEPTEMBER 25TH

7:15 am Break for the day

New Developments in Lung Cancer Therapeutics

9:10 am Panel Discussion: Navigating Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings

9:30 am Adjourn for the day

10:50 am Challenging Cases in Breast Cancer

11:20 am Q&A (Interactive Audience Participation): Breast Cancer

11:45 am New Developments in Lung Cancer Therapeutics

12:15 pm Q&A (Interactive Audience Participation): Lung Cancer

12:45 pm Adjourn for the day

SPEAKERS

Mehrdad Abedi, M.D.
Associate Professor of Medicine
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Kristie Bobolis, M.D.
Medical Oncologist
Capitol Hematology-Oncology

Richard Bold, M.D.
Professor of Medicine and Division Chief
Division of Surgical Oncology
UC Davis Comprehensive Cancer Center

Helen K. Chew, M.D.
Professor of Medicine
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Scott Christensen, M.D.
Professor of Medicine
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

David Cooke, M.D.
Assistant Professor
Assoc. Program Director, Cardiothoracic Surgery Residency
Division of Cardiothoracic Surgery
UC Davis Medical Center

Megan Daly, M.D.
Assistant Professor
Department of Radiation Oncology
UC Davis Comprehensive Cancer Center

Patricia A. Ganz, M.D.
Distinguished Professor Health Policy & Management and Medicine
UCLA Fielding School of Public Health
David Geffen School of Medicine at UCLA
Director, Cancer Prevention & Control Research
Jonsson Comprehensive Cancer Center

Tim Grennan, M.D.
Hematologist-Oncologist
Kaiser Permanente Medical Group, Morse

Richard Guy, M.D.
Hematologist-Oncologist
Kaiser Permanente Medical Group, Roseville

Laurence Heifitz, M.D.
Medical Oncology
Medical Director, Gene Upshaw Memorial Tahoe Forest Cancer Center

Brian Jonas, M.D., Ph.D.
Assistant Professor
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Karen Kelly, M.D.
Professor of Medicine
Division of Hematology and Oncology
Associate Director for Clinical Research
UC Davis Comprehensive Cancer Center

Edward Kim, M.D., Ph.D.
Assistant Professor
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Luko Laptalo, M.D.
Hematologist-Oncologist
Mercy Medical Group

Primo N. Lara, Jr., M.D.
Professor of Medicine
Division of Hematology and Oncology
Associate Director for Translational Research
UC Davis Comprehensive Cancer Center

Tianhong Li, M.D., Ph.D.
Assistant Professor
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Gilbert Mandell, M.D.
Volunteer Clinical Professor
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Ajithkumar Puthillath, M.D.
Hematologist-Oncologist
Stockton Hematology Oncology

David Quinn, MBBS, Ph.D.
Associate Professor of Medicine
University of Southern California Norris Comprehensive Cancer Center

Jonathan Riess, M.D.
Assistant Professor
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Thomas Semrad, M.D.
Assistant Professor
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Samer Shihabi, M.D.
Hematologist-Oncologist
Mercy Medical Group

Joseph Tuscano, M.D.
Professor of Medicine
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Ted Wun, M.D.
Professor of Medicine and Division Chief
Division of Hematology and Oncology
Associate Dean for Research
UC Davis Medical Center

The disclosure forms outlining this information will be made available to all participants prior to the symposium.
FRIDAY, SEPTEMBER 25TH (at UC Davis Comprehensive Cancer Center)

12:30 am Lunch
1:00 pm Introduction of Keynote Speaker: The Lois O’Grady Lectureship
   (Presentation of award to Dr. Patricia A. Ganz)
   Ted Wun, M.D.
   O’Grady Keynote Lecture
   Patricia A. Ganz, M.D.
   Question and Answer Session
2:00 pm Adjourn for the day

SATURDAY, SEPTEMBER 26TH (at Hyatt Regency Sacramento)

6:45 am Registration, coffee, visit exhibits
7:15 am Breakfast Symposia (non CME)
8:00 am Welcome Remarks
8:05 am Pre-session Survey
Scott Christensen, M.D.
8:10 am Keynote Lecture #1: The Lois O’Grady Lectureship
Patricia A. Ganz, M.D.
8:50 am Navigating Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings
Helen K. Chew, M.D.
9:10 am Panel Discussion: Challenging Cases in Breast Cancer
   Moderator: Helen K. Chew, M.D.
   Panel: Kristie Bobolis, M.D., Richard Bold, M.D., Scott Christensen, M.D.,
   Laurence Heifitz, M.D., Gilbert Mandell, M.D.
9:40 am Q&A (Interactive Audience Participation): Breast Cancer
9:45 am Keynote Lecture #2: “State of the Art in Genitourinary Cancers”
   David Quinn, MBBS, Ph.D.
10:15 am Refreshment break, visit exhibits
10:30 am New Developments in Lung Cancer Therapeutics
   Jonathan Riess, M.D.
10:50 am Panel Discussion: Translating Results of Trials in Small Cell and
   Non-Small Cell Lung Cancer into Clinical Practice
   Moderator: Jonathan Riess, M.D.
   Panel: David Cooke, M.D., Megan Daly, M.D., Tianhong Li, M.D., Ph.D.
   Karen Kelly M.D., Samer Shihabi, M.D.
11:20 am Q&A (Interactive Audience Participation): Lung Cancer
11:25 am Advances in Gastrointestinal Malignancies
   Edward Kim, M.D.
11:45 am Panel Discussion: Optimal Therapies in Gastrointestinal Cancers
   Moderator: Thomas Semrad, M.D.
   Panel: Richard Bold, M.D., Richard Guy, M.D., Edward Kim, M.D.,
   Luko Laptalo, M.D.
12:15 pm Q&A (Interactive Audience Participation): Gastrointestinal Cancers
12:20 pm Adjourn for Lunch
   12:30 – 1:00 pm Non CME Symposia
   1:00 – 1:30 pm Non CME Symposia
   1:30 – 1:45 pm Coffee, Dessert & Visit exhibits
1:45 pm Emerging Therapeutics in Hematologic Malignancies
   Brian Jonas, M.D., Ph.D.
2:05 pm Panel Discussion: Practice Changing Developments in Benign and Malignant
   Hematology
   Moderator: Joseph Tuscano, M.D.
   Panel: Mehrdad Abedi, M.D., Tim Grennan, M.D., Brian Jonas, M.D., Ph.D.,
   Ajithkumar Puthilath, M.D., Ted Wun, M.D.
2:35 pm Q&A (Interactive Audience Participation): Hematologic Malignancies
2:40 pm Recent and Late Breaking Developments in Cancer Therapy
   Thomas Semrad, M.D.
3:00 pm Post-session Survey/Closing Remarks
   Scott Christensen, M.D.
The 16th Annual Advances in Oncology program will bring together academic oncologists, community oncologists for the purpose of educating participants on the state-of-the-art developments in oncology care in the context of local treatment approaches, patient care, and oncology conferences to be presented and discussed. This educational activity in the fall allows for the latest findings in clinical cancer research from major hematology and oncology conferences to be presented and discussed.

EDUCATIONAL OBJECTIVES

1. Understand the need for cutting-edge information on prognostic markers and appropriate application in therapeutic decision making.
2. Discuss the application and challenges of new prognostic developments in oncology care in the context of local treatment approaches.
3. Evaluate how to rapidly evolving. The development of personalized medicine.
4. Apply data from recent clinical trials to determine the optimal course of therapy.

PANELISTS

Mehrdad Abedi, M.D.
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Edward Kim, M.D., Ph.D.
Division of Hematology and Oncology
Kaiser Permanente Medical Group, Morse Capitol Hematology-Oncology

Primo N. Lara, Jr., M.D.
Hematologist-Oncologist
Division of Hematology and Oncology
UC Davis Medical Center

Megan Daly, M.D.
Assistant Professor
Division of Hematology and Oncology
UC Davis Medical Center

Thomas Semrad, M.D.
Assistant Professor
Division of Hematology and Oncology
UC Davis Medical Center

David Quinn, MBBS, Ph.D.
Associate Director for Translational Research
UC Davis Medical Center

Ajithkumar Puthillath, M.D.
Assistant Professor
Division of Hematology and Oncology
UC Davis Medical Center

Karen Kelly M.D., Samer Shihabi, M.D.
Panel: David Cooke, M.D., Megan Daly, M.D., Tianhong Li, M.D., Ph.D.

Jonathan Riess, M.D.
Professor of Medicine and Division Chief, Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Ted Wun, M.D.
Hematologist-Oncologist
Division of Hematology and Oncology
UC Davis Medical Center

Joseph Tuscano, M.D.
Assistant Professor
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Scott Christensen, M.D.
Moderator:
UC Davis Comprehensive Cancer Center

FRIDAY, SEPTEMBER 25TH

8:05 am
Navigating Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings

8:10 am
Q&A (Interactive Audience Participation): Lung Cancer

8:50 am
Introduction of Keynote Speaker: The Lois O’Grady Lectureship

10:15 am
Refreshment break, visit exhibits

11:15 am
Non-Small Cell Lung Cancer into Clinical Practice

12:15 pm
Panel Discussion: Translating Results of Trials in Small Cell and Non-Small Cell Lung Cancer into Clinical Practice

12:30 – 1:00 pm Non-CME Symposia

1:45 pm
Panel: David Cooke, M.D., Megan Daly, M.D., Tianhong Li, M.D., Ph.D.

16th Annual Advances in Oncology 2015
September 25 - 26, 2015
Hyatt Regency
Sacramento, CA

For more information contact:

MECC
1550 S Dixie Highway Suite 202, Coral Gables, FL 33146
Telephone 305/663-1628
Fax 305/675-2718
Or visit our website at www.meccinc.com
Email: tvalls@meccinc.com
NAME _____________________________________________ DEGREE __________________

ADDRESS ____________________________________________________________________

CITY ___________________________ STATE ___________________ ZIP ___________

TELEPHONE (___)___________________________ FAX (____)________________________

EMAIL ADDRESS ____________________________________________________________

SPECIALTY ___________________________________________________________________

LICENSE# ___________________________ STATE OF LICENSE ______________________

TYPE OF PRACTICE:

q Private
q Academic
q Hospital
q Resident/Fellow

I will be attending

q BOTH days September 25 and 26
q ONLY Friday September 25 at the UC Davis Comprehensive Cancer Center
q ONLY Saturday, September 26 at the Hyatt Regency

REGISTRATION FEE

$150 Physicians
$ 75 Nurses, Fellows, Residents and Allied Health Care
$250 Industry Professionals

Refunds must be provided in writing prior to August 25, 2015. After August 25, 2015,
No Refunds will be provided. A $50.00 administrative fee is charged on all refunds.

ENCLOSED IS MY CHECK i/a/o of _____ FOR REGISTRATION OF THIS COURSE.

I AUTHORIZE MECC TO CHARGE MY CREDIT CARD i/a/o $_______ FOR REGISTRATION OF THIS COURSE USING THE FOLLOWING CREDIT CARD.

NAME ON CARD _______________________________________ EXP. DATE____________

CARD NUMBER _______________________________________ CVV CODE____________

AUTHORIZED SIGNER ___________________________________________________________

CONFERENCE LOCATION

This conference is held at two locations. No transportation will be provided from the
host hotel.

Parking is available in the lot adjacent to the Cancer Center.

For more information contact:

CONFERENCE MANAGEMENT

MEC 1550 S Dixie Highway Suite 202, Coral Gables, FL  33146

Telephone 305/663-1628 Office Fax 305/675-2718

Or visit our website at www.meccinc.com

EMAIL: tvalls@meccinc.com

CONFERENCE DIRECTORS

Helen K. Chew, M.D.
Professor of Medicine
Division of Hematology and Oncology
Department of Internal Medicine
UC Davis School of Medicine

Primo Lara, Jr., M.D.
Professor of Medicine
Division of Hematology and Oncology
Department of Internal Medicine
UC Davis School of Medicine

PRESENTED BY

SPONSORED BY:

THE MEDICAL EDUCATOR

CONSORTIUM

COMPREHENSIVE CANCER CENTER

16th Annual Advances in Oncology 2015

MECC, Inc.
1550 South Dixie Highway, Suite 202
Coral Gables, Florida 33146